Brigade Capital Management LP Purchases New Position in Lumexa Imaging Holdings, Inc. $LMRI

Brigade Capital Management LP acquired a new stake in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 665,900 shares of the company's stock, valued at approximately $7,511,000. Lumexa Imaging makes up 1.4% of Brigade Capital Management LP's portfolio, making the stock its 5th largest holding. Brigade Capital Management LP owned 0.69% of Lumexa Imaging at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LMRI. Janus Henderson Group PLC lifted its stake in Lumexa Imaging by 5.4% during the first quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company's stock worth $18,063,000 after purchasing an additional 107,903 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in shares of Lumexa Imaging during the fourth quarter worth $37,139,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Lumexa Imaging during the 4th quarter worth approximately $27,750,000. ArrowMark Colorado Holdings LLC acquired a new stake in shares of Lumexa Imaging during the fourth quarter worth $27,750,000. Finally, Invesco Ltd. bought a new position in shares of Lumexa Imaging during the fourth quarter worth $26,562,000.

Analyst Upgrades and Downgrades

LMRI has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft set a $16.00 price target on Lumexa Imaging in a research report on Thursday, August 13th. Weiss Ratings upgraded Lumexa Imaging from a "sell (e)" rating to a "sell (d)" rating in a research note on Thursday, June 25th. Wall Street Zen upgraded shares of Lumexa Imaging from a "hold" rating to a "buy" rating in a report on Sunday, August 16th. Finally, Barclays dropped their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $16.00.

Lumexa Imaging Stock Down 4.6%

Shares of NASDAQ LMRI opened at $11.85 on Tuesday. The company has a market cap of $1.14 billion and a price-to-earnings ratio of -24.18. The firm's fifty day moving average is $11.19 and its 200 day moving average is $10.85. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. Lumexa Imaging Holdings, Inc. has a 52 week low of $6.45 and a 52 week high of $19.45.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.17. The firm had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. On average, equities research analysts expect that Lumexa Imaging Holdings, Inc. will post 0.32 earnings per share for the current year.

Lumexa Imaging Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source